REVIEWS

From Krebs to clinic: glutamine metabolism to cancer therapy

Brian J. Altman[1–3], Zachary E. Stine[1–3] and Chi V. Dang[1–3]

Abstract | The resurgence of research into cancer metabolism has recently broadened interests beyond glucose and the Warburg effect to other nutrients, including glutamine. Because oncogenic alterations of metabolism render cancer cells addicted to nutrients, pathways involved in glycolysis or glutaminolysis could be exploited for therapeutic purposes. In this Review, we provide an updated overview of glutamine metabolism and its involvement in tumorigenesis *in vitro* and *in vivo*, and explore the recent potential applications of basic science discoveries in the clinical setting.

Glucose has been central to the study of cancer metabolism following Otto Warburg's pioneering work on aerobic glycolysis[1], whereas studies of other nutrients, such as glutamine, have been at the margins of the cancer metabolism literature until recently. Hans Krebs, famed for characterization of the tricarboxylic acid (TCA) cycle, studied glutamine metabolism in animals in 1935 and documented its importance in organismal homeostasis. Subsequently, the role of glutamine in cell growth and cancer cell biology has slowly been appreciated (FIG. 1) and has been a subject of several comprehensive reviews[2,3]. Given the many energy-generating and biosynthetic roles that glutamine plays in growing cells, which are discussed and updated in this Review, inhibition of glutaminolysis has the potential to effectively target cancer cells.

There are nine amino acids (isoleucine, leucine, methionine, valine, phenylalanine, tyrosine, histidine, threonine and lysine) that humans cannot synthesize and hence are considered essential amino acids. Five amino acids (alanine, aspartate, asparagine, glutamate and serine) are believed to be dispensable, because they can be readily synthesized. Glutamine belongs to a group of amino acids that are conditionally essential, particularly under catabolic stressed conditions such as the postoperative period, injury or sepsis, in which glutamine consumption by the kidney, gastrointestinal tract and immune compartment rises dramatically[4]. Cells of the intestinal mucosa are particularly dependent on glutamine, and they rapidly undergo necrosis after glutamine depletion[4]. These observations mirror the dependence of growing cancer cells on glutamine[5], with some cancer cells dying rapidly if they are deprived of glutamine[6].

Circulating glutamine is the most abundant amino acid (~500 μM)[7], making up more than 20% of the free amino acid pool in blood and 40% in muscle[8]. Although diet can serve as a source of glutamine from digested foods absorbed through the small intestine, the endothelium of which retains up to 30% of dietary glutamine, glutamine can be considered a non-essential amino acid at the organismal level owing to the fact that the muscle and other organs synthesize glutamine as a scavenger for ammonia produced by the metabolism of other amino acids[9]. In fact, glutamine is held at a fairly constant level in the circulation, presumably owing to *de novo* synthesis and release from the skeletal muscle, lung and adipose tissue[3,10,11]. The kidney releases ammonia from glutamine to maintain acid–base homeostasis[12], and the liver and kidney eliminate excess nitrogen in the form of urea from glutamine via the urea cycle, another process first identified by Krebs[13]. In rapidly dividing cells such as lymphocytes, enterocytes of the small intestine and especially cancer cells, glutamine is avidly consumed and used for both energy generation and as a source of carbon and nitrogen for biomass accumulation[14].

Glutamine metabolism

The maintenance of high levels of glutamine in the blood provides a ready source of carbon and nitrogen to support biosynthesis, energetics and cellular homeostasis that cancer cells may exploit to drive tumour growth. Glutamine is transported into cells through one of many transporters[15], such as the heavily studied SLC1A5 (also known as ASCT2; FIG. 2)[16], and can then be used for biosynthesis or exported back out of the cell by antiporters in exchange for other amino acids such as leucine, through the L-type amino acid transporter 1 (LAT1, a heterodimer of SLC7A5 and SLC3A2) antiporter[17]. Glutamine-derived glutamate can also be exchanged through the xCT (a heterodimer of SLC7A11 and SLC3A2; FIG. 3) antiporter for cystine, which is quickly reduced to cysteine inside the cell[18].

[1]*Abramson Family Cancer Research Institute, University of Pennsylvania.*
[2]*Abramson Cancer Center, University of Pennsylvania.*
[3]*Division of Hematology–Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.*

Correspondence to C.V.D.
dangvchi@exchange.upenn.edu

doi:10.1038/nrc.2016.71
Published online 29 July 2016

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.



Figure 1 | **Timeline of key discoveries in mammalian glutamine metabolism and cancer.** α-KG, α-ketoglutarate; GLUD, glutamate dehydrogenase.

Macropinocytosis
A type of endocytosis in which extracellular fluid and nutrients are engulfed and taken up into vesicles called macropinosomes. The contents can then be digested by lysosomal degradation to provide nutrients for metabolism.

Autophagy
Refers to macroautophagy, which is a process of bulk cytoplasmic and organelle degradation by specialized organelles called autophagosomes, which then deliver the contents to the lysosome. Autophagy is increased under many forms of stress and can provide nutrients for metabolism.

Aminotransferases
A class of enzymes, also known as transaminases, that catalyse the reaction between an α-keto acid such as pyruvate and an α-amino acid to form a different amino acid and α-keto acid. For example, glutamate–pyruvate transaminase (GPT, also known as alanine aminotransferase) transfers a nitrogen from glutamate to pyruvate to make alanine and α-ketoglutarate.

Oncogenotypes
The genetic or epigenetic alterations (to activate an oncoprotein or disable a tumour suppressor pathway) that drive the evolution and phenotype of a given tumour.

In addition to transport, cancer cells can acquire glutamine through the breakdown of macromolecules under nutrient-deprived conditions. Macropinocytosis, which can have a role in normal biology and is active in most non-cancerous cells[19], can be stimulated by oncogenic RAS[20], enabling cancer cells to scavenge extracellular proteins, which are then degraded to amino acids, including glutamine, supplying metabolites for survival[21,22]. This process must be tightly controlled[23], as excess RAS can hyperactivate macropinocytosis, leading to cell death, in a process previously misidentified as autophagic cell death[24]. The complex relationship between glutamine metabolism and autophagy is discussed below, but it is notable that some RAS-transformed cancer cells derive glutamine and maintain metabolic flux from autophagic degradation of intracellular proteins[25,26].

Energy generation. Upon entry into the cell via transporters, glutamine is converted by mitochondrial glutaminases to an ammonium ion and glutamate, which is further catabolized through two different pathways (FIG. 2). Interestingly, despite its importance, the mitochondrial glutamine transporter has not yet been definitively identified and characterized[27]. Glutaminase, which, as Krebs determined, exists in multiple tissue-specific versions, is encoded by two genes in mammals, kidney-type glutaminase (*GLS*) and liver-type glutaminase (*GLS2*)[28,29]. Glutamate can then be converted to α-ketoglutarate, which enters the TCA cycle to generate ATP through production of NADH and $FADH_2$. As Lehninger first described[30], glutamate can be converted to α-ketoglutarate by either glutamate dehydrogenase (encoded by the highly conserved and more broadly expressed *GLUD1* or the hominoid-specific *GLUD2*, henceforth collectively termed GLUD), which is an ammonia-releasing process, or by several non-ammonia-producing aminotransferases, which transfer nitrogen from glutamate to produce another amino acid and α-ketoglutarate[30]. Proliferating cells including cancer cells and activated lymphocytes use glutamine as an energy-generating substrate[31–33]. In some tumour cells, a portion of metabolized glutamine is converted to pyruvate through the malic enzymes[31,34], but as discussed below, this is probably not an energy-generating process. Notably, and as will be expanded on below, proliferating cells incorporate most of the glutamine they use for biomass for building protein and nucleotides[35].

Glutamine enzymes in cancer. The expression of enzymes involved in glutamine metabolism varies widely in cancers and is affected by tissue of origin and oncogenotypes, which rewire glutamine metabolism for energy generation and stress suppression. Of the two glutaminase enzymes[28], *GLS* is more broadly expressed in normal tissue and is thought to have a crucial role in many cancers, whereas *GLS2* expression is restricted primarily to the liver, brain, pituitary gland and pancreas[36]. Alternative splicing adds further complexity, as *GLS* pre-mRNA is spliced into either glutaminase C (GAC) or kidney-type glutaminase (KGA) isoforms[37–39]. The two GLS isoforms and GLS2 also differ in their regulation and activity. GLS but not GLS2 is inhibited by its product glutamate, whereas GLS2 but not GLS is activated by its product ammonia *in vitro*[28,29]. Although both GLS and GLS2 are activated by inorganic phosphate, GLS (and particularly GAC) shows a much larger increase in catalysis in the presence of inorganic phosphate[37]. Sirtuin 5 (SIRT5), which can be overexpressed in lung cancer[40], can desuccinylate GLS to suppress its enzymatic activity[41], whereas SIRT3 can deacetylate GLS2 to promote its increased activity with caloric restriction[42]. The availability of phosphate, acetyl-CoA and succinyl-CoA is affected by nutrient uptake and metabolism, suggesting that GLS and GLS2 activity may be responsive to the metabolic state of the cell. Additionally, GLS is regulated through transcription[43], RNA-binding protein regulation of

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.



Figure 2 | **Major metabolic and biosynthetic fates of glutamine.** Glutamine enters the mammalian cell through transporters such as SLC1A5 (also known as ASCT2)[15]. Glutamine itself can contribute to nucleotide biosynthesis and uridine diphosphate *N*-acetylglucosamine (UDP-GlcNAc) synthesis for support of protein folding and trafficking[210], or is converted to glutamate by glutaminase (GLS or GLS2)[28]. Glutamate can contribute to the synthesis of glutathione[110] and has many other metabolic fates in the cell that have an impact on several inborn errors of metabolism, which were recently reviewed[211]. Glutamate is converted to α-ketoglutarate (α-KG) through one of two sets of enzymes, glutamate dehydrogenase (GLUD1 or GLUD2, henceforth referred to collectively as GLUD) or aminotransferases[30]. Whereas the by-product of GLUD is NH_4^+, the by-product of aminotransferase reactions is other amino acids. Note that aminotransferases may be present in either the cytoplasm or the mitochondria. α-KG enters the tricarboxylic acid (TCA) cycle and can provide energy for the cell. Malate exiting the TCA cycle can produce pyruvate and NADPH for reducing equivalents[31], and oxaloacetate (OAA) can be converted into aspartate to support nucleotide synthesis[34]. These two pathways are illustrated in more detail in FIG. 4. Alternatively, α-KG can proceed backwards through the TCA cycle, in a process called reductive carboxylation (RC) to produce citrate, which supports synthesis of acetyl-CoA and lipids[87].

alternative splicing[44–47], post-transcriptional regulation by microRNAs (miRNAs) and pH stabilization of the *GLS* mRNA[48,49], and protein degradation via the anaphase-promoting complex (APC)–CDH1 (also known as FZR1) E3 ubiquitin ligase complex[50,51].

Expression of GAC, which is more active than KGA, is increased in several cancer types, suggesting that *GLS* alternative splicing may have an important role in the presumed higher glutaminolytic flux in cancer[18,37,45,47,52–54]. By contrast, the role of GLS2 in cancer seems more complex. Silenced by promoter methylation in liver cancer, colorectal cancer and glioblastoma, re-expression of *GLS2* has been shown to have tumour suppressor activities in colony formation assays[55–59]. In fact, a recent study[60] showed that GLS2, in a non-metabolic function, sequesters the small GTPase RAC1 to suppress metastasis. However, GLS2 seems to support growth and promote ionizing radiation resistance in some types of cancer[61]. Indeed, GLS2 is induced by the tumour suppressor p53 and related proteins p63 and p73 (REFS 55,56,62,63), suggesting that perhaps it functions in resistance to ionizing radiation, or is important in cancers that still possess wild-type p53. Additionally, GLS2 is a crucial downstream target of the NMYC oncoprotein in neuroblastoma[64,65]. The context-dependent role of GLS2 in cancer clearly merits further study.

Once produced via glutaminase, glutamate is further converted to α-ketoglutarate through one of two mechanisms[30] (FIG. 2). GLUD catalyses the reversible deamination of glutamate to produce α-ketoglutarate and release ammonium. This reaction is at near-thermodynamic equilibrium in the liver, and so GLUD operates in both directions in this organ[66], but in cancer it is thought to operate chiefly in the direction of α-ketoglutarate[67], and so GLUD activity will be discussed in this context for the purpose of this Review. Like GLS, GLUD is controlled through post-translational modifications and allosteric regulation. It is activated by ADP and inactivated by GTP, palmitoyl-CoA and SIRT4-dependent ADP ribosylation[68–71]. Interestingly, GLUD is also allosterically activated by leucine, and mTOR (which itself is activated by leucine availability[17,72]) can promote GLUD activity by suppressing SIRT4 expression[73,74]. These observations suggest that a low energetic state might induce GLUD allosterically via ADP to increase ATP production, and high leucine availability could also induce GLUD allosterically and through mTOR-mediated suppression of SIRT4.

Aminotransferases are enzymes that convert glutamate to α-ketoglutarate without producing ammonia (FIG. 3). Two of these enzymes, alanine aminotransferase and aspartate aminotransferase, are well known in clinical medicine as 'liver enzymes' or markers of liver pathology[75,76]. Glutamate–pyruvate transaminase (GPT, also known as alanine aminotransferase) transfers nitrogen from glutamate to pyruvate to make alanine and α-ketoglutarate, and is encoded in humans by *GPT* (cytoplasmic isoform) and *GPT2* (mitochondrial isoform). Glutamate–oxaloacetate transaminase (GOT, also known as aspartate aminotransferase), which transfers nitrogen from glutamate to oxaloacetate to produce aspartate and α-ketoglutarate, is encoded in humans by *GOT1* (cytoplasmic isoform) and *GOT2* (mitochondrial isoform). Phosphoserine aminotransferase 1 (*PSAT1*), as part of the serine biosynthesis pathway, transfers nitrogen from glutamate to 3-phosphohydroxypyruvate to make phosphoserine and α-ketoglutarate. Different aminotransferases show different tissue distribution: aspartate aminotransferase activity is high across most tissues, whereas alanine aminotransferase activity is highest in the liver, although expression is still fairly universal[36,77,78]. However, aminotransferases such as *PSAT1* may be inappropriately expressed in tumours[79]. The potential importance of which enzyme converts glutamate to α-ketoglutarate in cancer cell physiology is discussed below.

Glutamine and ATP: what else?

Amino acid production. The nitrogen from glutamine supports the levels of many amino acid pools in the cell through the action of aminotransferases[35] (FIG. 3).

Caloric restriction
Restricting the available calories to a model organism, such as a mouse or *Caenorhabditis elegans*, without undernourishing them. Caloric restriction has been shown in several species to delay age-associated diseases and dramatically extend lifespan.

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.



Figure 3 | **Glutamine control of amino acid pools and reactive oxygen species.** Glutamate acts as a nitrogen donor for the transamination involved in the production of 'dispensable amino acids' — alanine, aspartate and serine — through the actions of glutamate–oxaloacetate transaminase (GOT), glutamate–pyruvate transaminase (GPT) and phosphoserine aminotransferase 1 (PSAT1), respectively. Glutamine can also act as a nitrogen donor for asparagine through asparagine synthetase (ASNS). In a reaction independent of transamination, proline can be synthesized by conversion of glutamate to pyrroline-5-carboxylate (P5C) by pyrroline-5-carboxylate synthase (P5CS; also known as ALDH18A1) and subsequently to proline by pyrroline-5-carboxylate reductase 1 (PYCR1) and PYCR2. Glutamine also contributes to the tripeptide glutathione (composed of glutamate, cysteine and glycine), which neutralizes the reactive oxygen species (ROS), including H_2O_2 (REF. 110). The first step in glutathione synthesis is the condensation of glutamate and cysteine through glutamate–cysteine ligase (GCL; not shown in the figure). Glutamine input contributes directly to the availability of cysteine and glycine for production of glutathione. Glutamate can be exchanged for cystine (which is quickly reduced to cysteine inside the cell) through the xCT antiporter (a heterodimer of SLC7A11 and SCL3A2), which has been shown to be important in various cancers and has been considered as a drug target[18,212]. Glycine is next added by glutathione synthetase (GSS; not shown in the figure). Additionally, glutamate can contribute to glycine through transamination by PSAT1 into phosphoserine (pSer) and α-ketoglutarate (α-KG) and subsequent conversion to glycine through serine hydroxymethyltransferase (SHMT; not shown in the figure) as part of the one-carbon metabolism pathway, which has been shown in numerous studies to be crucial in cancer metabolism and is also reviewed in this Focus issue by Vousden[139,140,213]. GLS, kidney-type glutaminase; GLS2, liver-type glutaminase; GLUD, glutamate dehydrogenase; OAA, oxaloacetate.

One-carbon metabolism pathway
A pathway centred on the metabolism of folate, an important carbon donor for DNA methylation and purine nucleotide synthesis. This pathway is linked to the *de novo* biosynthesis pathways of serine and glycine.

Reductive carboxylation
A process that occurs in some normal and cancer cells whereby α-ketoglutarate proceeds 'backwards' through the tricarboxylic acid cycle, being reduced through the consumption of NADPH by isocitrate dehydrogenase in the non-canonical reverse reaction to form citrate. This citrate may then be used in fatty acid synthesis.

Integrated stress response (ISR)
A stress response pathway that responds to various cellular insults, including amino acid deprivation, through the GCN2 kinase, to phosphorylate eukaryotic translation initiation factor 2α (eIF2α), halt general cap-dependent protein translation and increase transcription of endoplasmic reticulum chaperone proteins. The ISR may eventually result in apoptotic cell death if the stress is not resolved.

Separate from transamination reactions, carbon and nitrogen from glutamate can be used to produce proline, which has a key role in the production of the extracellular matrix protein collagen[80] (FIG. 3). Although proline can be degraded to glutamate[81], the MYC oncoprotein can alter the expression of proline synthesis and degradation enzymes to promote the net synthesis of proline from glutamine-derived glutamate[82]. Overall, tracer experiments determined that at least 50% of non-essential amino acids used in protein synthesis by cancer cells *in vitro* can be directly derived from glutamine[16,83]. Although various glutamine-derived amino acids contribute to cancer cell survival, recent studies have shown that aspartate biosynthesis, which can depend on both glutamine flux through the TCA cycle and glutamate transamination[84,85], is especially crucial owing to its key role in both purine and pyrimidine biosynthesis to support cell division[84–86], as discussed in greater detail below.

Reductive carboxylation and fatty acid synthesis. Cancer cells take up large amounts of glucose, but most of this carbon is excreted as lactate rather than being metabolized in the TCA cycle[7], potentially depriving the cells of the citrate derived from the TCA cycle that supports fatty acid synthesis (FIG. 2). Glutamine metabolism can serve as an alternative source of carbon to the TCA cycle to fuel fatty acid synthesis, through reductive carboxylation, which is a process by which glutamine-derived α-ketoglutarate is reduced through the consumption of NADPH by isocitrate dehydrogenases (IDHs) in the non-canonical reverse reaction, to form citrate[87]. Reductive carboxylation, the importance of which is still somewhat controversial[88], seems to be a major source of carbon for lipid synthesis in cancer cells that are hypoxic, have constitutive hypoxia-inducible factor-α (HIFα) stabilization or have mitochondrial defects[89–92]. Although the contribution of reductive carboxylation to lipid formation from glutamine remains unclear owing to the possibility of isotope exchange[88], studies suggest that reductive carboxylation occurs *in vivo* and can support lipogenesis for tumour growth and progression[89,93,94] and can also control the levels of mitochondrial reactive oxygen species (ROS)[95].

Protein synthesis, trafficking and stress pathway suppression. Several of the metabolic fates of glutamine directly support protein synthesis and trafficking, and suppress stress responses carried out by two related pathways — the integrated stress response (ISR) and

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.

Endoplasmic reticulum (ER) stress
Refers to various stresses that lead to protein misfolding and activate the unfolded protein response (UPR). The UPR, which shares molecular machinery with the integrated stress response, halts cap-dependent translation, induces expression of ER chaperone proteins and can lead to death if the stress is not resolved.

Cap-dependent translation
In most eukaryotic mRNAs, translation relies on eukaryotic translation initiation factor 4E (eIF4E) binding to the 5′ mRNA cap (a modified nucleotide), along with the ribosome and other initiation factors. Certain stress pathways including endoplasmic reticulum stress and the integrated stress response inhibit cap-dependent translation through inhibitory phosphorylation of the initiation factor eIF2α.

the endoplasmic reticulum (ER) stress pathway (FIG. 4). Glutamine input thus supports the overall amino acid pools of the cell to suppress the ISR, which is otherwise activated under amino acid deprivation by the amino acid-sensing kinase GCN2 (encoded by *EIF2AK4*) (FIG. 3). Phosphorylation of eukaryotic translation initiation factor 2α (eIF2α) by GCN2 inhibits general cap-dependent translation via the ISR but induces cap-independent synthesis of the activating transcription factor 4 (ATF4), which in turn induces a pathway to increase transcription of ER-associated chaperones, halt cap-dependent translation and eventually result in cell death[96]. Glutamine deprivation can lead directly to uncharged tRNAs, or to a depletion of downstream products such as asparagine, which leads indirectly to uncharged tRNAs, all of which can activate GCN2 and induce ATF4 translation. Suppression of the ISR by glutamine input has been shown to be crucial for the survival of several cancer cell and tumour types, including neuroblastoma and breast cancer[65,97,98]. It was also observed that GCN2 is activated in mice in response to treatment with asparaginase[99], which is approved by the US Food and Drug Administration (FDA) for the treatment of acute lymphoblastic leukaemia (ALL) and may deplete serum asparagine and glutamine[100–102].



Figure 4 | **Control by glutamine of the integrated stress response, protein folding and trafficking, and endoplasmic reticulum stress.** The amino acid-sensing kinase GCN2, a serine–threonine kinase with a regulatory domain that is structurally similar to histidine-tRNA synthetase, is allosterically activated by uncharged tRNAs with amino acid deprivation (including glutamine deprivation) and in turn activates the integrated stress response (ISR)[96,214,215]. Glutamine can suppress GCN2 activation through its contribution to amino acid pools by aminotransferases[65,97–99]. To control endoplasmic reticulum (ER) homeostasis, glutamine supports protein folding and trafficking through its contribution to uridine diphosphate *N*-acetylglucosamine (UDP-GlcNAc) as part of the hexosamine biosynthesis pathway. Glutamine is the substrate for glutamine fructose-6-phosphate aminotransferase (GFAT), which is the key rate-limiting enzyme in the hexosamine pathway, and the downstream product UDP-GlcNAc is a substrate for *O*-linked glycosylation through *O*-linked β-*N*-acetylglucosamine transferase (OGT). Thus, glutamine deprivation can lead to improper protein folding and chaperoning and ER stress[210]. A key output of both the ISR and ER stress is activating transcription factor 4 (ATF4), which is induced via cap-independent translation downstream of eukaryotic translation initiation factor 2α (eIF2α) phosphorylation by GCN2 or other kinases[96]. α-KG, α-ketoglutarate; GLS, kidney-type glutaminase; GLS2, liver-type glutaminase.

Glutamine also contributes to the synthesis of uridine diphosphate *N*-acetylglucosamine (UDP-GlcNAc) as part of the hexosamine biosynthesis pathway, which is required for glycosylation, proper ER–Golgi trafficking and suppression of the ER stress pathway, also upstream of ATF4 induction (FIG. 4). Aberrant expression and activity of O-linked β-*N*-acetylglucosamine transferase (OGT), which links UDP-GlcNAc to proteins, was shown to be crucial for the survival and progression of breast cancer, prostate cancer and chronic lymphocytic leukaemia[103–105]. Thus, glutamine input directly maintains translation, protein trafficking and survival through suppression of the ISR and the ER stress pathway[106,107].

ROS control: glutathione and reducing equivalents. ROS-mediated cell signalling can be pro-tumorigenic when at physiological levels[108], but when levels are in excess, ROS can be highly damaging to macromolecules[109]. ROS are generated from several sources, including the mitochondrial electron transport chain, which can leak electrons to oxygen to generate superoxide (O_2^-). Thus, increased glutamine oxidation can correlate with increased ROS production[108]. However, several glutamine metabolic pathways lead to products that directly control ROS levels; hence, glutamine metabolism is crucial for cellular ROS homeostasis. The best known pathway by which glutamine controls ROS is through synthesis of glutathione. Glutathione is a tripeptide (Glu-Cys-Gly) that serves to neutralize peroxide free radicals. It has long been appreciated that glutamine input is the rate-limiting step for glutathione synthesis[110], and as shown in FIG. 3, glutamine is directly and indirectly responsible for the other two amino acid components of glutathione. As glutathione levels are known to correlate with tumorigenesis and drug resistance in cancer[111], a richer understanding of this pathway may contribute to better cancer treatment strategies. In fact, several studies have shown that acute administration of glutamine to cancer patients receiving radiotherapy or chemotherapy reduces treatment toxicity through increased glutathione synthesis[112,113]. Glutamine also affects ROS homeostasis through production of NADPH via GLUD[114]. Additionally, at least two other related mechanisms provide reducing equivalents for glutathione[31,34], by which TCA cycle-derived aspartate or malate is exported to the cytoplasm and then converted to pyruvate to produce NADPH through the malic enzymes. FIGURE 5 details two glutamine-derived pathways, one of which is mediated by oncogenic KRAS[34].

Regulation of mTOR. The TOR pathway senses amino acids and broadly promotes biosynthetic pathways such as protein translation and fatty acid synthesis while inhibiting degradative processes like autophagy[115]. As such, mTOR activity must be tightly controlled to prevent inappropriate cell growth, and glutamine regulates this activity through several mechanisms (FIG. 6). Amino acid availability stimulates mTOR activity independently of the activating mTOR pathway mutations often found in human cancer[115], and thus must be maintained regardless of mutation state. Glutamine and other amino acids that support mTOR activity need not come from amino

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.



Figure 5 | **Glutamine-derived TCA cycle intermediates can be used via two pathways to produce NADPH and neutralize reactive oxygen species through the malic enzyme.** Reduced glutathione (GSH) neutralizes H_2O_2 with the glutathione peroxidase enzyme, and oxidized glutathione (GSSG) is reduced by NADPH and glutathione reductase to regenerate GSH. In the first pathway, glutamine-derived malate is transported out of the mitochondria, and is converted by malic enzyme 1 (ME1) into pyruvate, reducing one molecule of $NADP^+$ to NADPH. In the malate–aspartate shuttle-related second pathway, found in mutant KRAS-transformed cells, aspartate that is produced from glutamate–oxaloacetate transaminase mitochondrial isoform (GOT2)-mediated transamination of glutamine-derived oxaloacetate (OAA) is transported out of the mitochondria. Aspartate is then converted in the cytosol back to OAA by GOT1 and then to malate by malate dehydrogenase 1 (MDH1), which is in turn processed to pyruvate by ME1 to produce one molecule of NADPH[34]. The fate of glutamine-derived pyruvate is similar to that of glucose-derived pyruvate in that much of it is expelled as lactate[31]. α-KG, α-ketoglutarate; TCA, tricarboxylic acid.

acid transporters, as macropinocytosis-derived amino acids can also support mTOR activation[23]. Conversely, mTOR itself can regulate glutamine metabolism by cell-type specific mechanisms, either by inhibiting expression of mitochondrial SIRT4, thereby relieving repression of GLUD[69,73,116], or instead by inhibiting GLUD expression while upregulating expression of aminotransferases[117], as is discussed further below. The important implication of these findings is that, independently of direct mutations of negative regulators of the mTOR pathway itself, such as tuberous sclerosis 1 (TSC1; also known as hamartin) and TSC2 (also known as tuberin), increased glutamine uptake and metabolism, which is common in many cancers, may also strongly stimulate mTOR activity. The regulation of mTOR by amino acid availability, including that of glutamine, is a rich and evolving field, and more advances will be needed to fully understand this intriguingly intricate process[115].

Nucleotide biosynthesis. Glutamine directly supports the biosynthetic needs of cell growth and division. Whereas carbon from glutamine is used for amino acid and fatty acid synthesis, nitrogen from glutamine contributes directly to *de novo* biosynthesis of both purines and pyrimidines[118]. The importance of glutamine as a nitrogen reservoir is underscored by the fact that glutamine-deprived cancer cells undergo cell cycle arrest that cannot be rescued by TCA cycle intermediates such as oxaloacetate but can be rescued by exogenous nucleotides[118,119]. In fact, synthesis of nucleotides from exogenous glutamine has been observed in human primary lung cancer samples cultured *ex vivo*[120].

Glutamine can also contribute to nucleotide biosynthesis through other pathways. Aspartate derived from glutamine via the TCA cycle and transamination (FIGS 2,3) serves as a crucial source of carbon for purine and pyrimidine synthesis[84,85], and provision of aspartate can rescue cell cycle arrest caused by glutamine deprivation[86]. Additionally, glutamine-dependent mTOR signalling may activate the enzyme carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), which catalyses the incorporation of glutamine-derived nitrogen into pyrimidine precursors[118,121,122]. It has been suggested that NADPH produced downstream of glutamine metabolism and flux through the malic enzymes can further support nucleotide synthesis[31]. Overall, glutamine can support biomass accumulation of fatty acids, amino acids and nucleotides, by directly contributing carbon and nitrogen, indirectly generating reducing equivalents and stimulating the signalling pathways that are necessary for their synthesis.

Autophagy and glutamine. Autophagy and glutamine have a complex relationship that mirrors the complexities of autophagy in cancer initiation and progression. The role of autophagy in cancer seems paradoxical: in some settings, it is tumour suppressive, by limiting the oxidative stress and chromosomal instability that may lead to oncogenic mutations[123,124], whereas in other situations, autophagy supports cancer cell survival by providing nutrients and suppressing stress pathways such as p53 (REFS 125,126). Thus, autophagy may influence tumour initiation and tumour progression differently, affecting tumour growth in a seemingly contradictory context-dependent manner. Many of the processes affected by glutamine metabolism suppress autophagy. Glutamine suppresses GCN2 activation and the ISR, both of which can otherwise induce autophagy[65,97,127]. Glutamine also indirectly stimulates mTOR, which in turn suppresses autophagy through a complex mechanism[17,128–134] (recently reviewed by Dunlop and Tee[135]). Similarly, ROS can induce autophagy as a stress response[136] but are suppressed by glutamine metabolism through production of glutathione and NADPH[31,34,110]. Conversely, generation of ammonia from glutaminolysis could potentially promote autophagy activation in an autocrine and paracrine manner[137,138]. Although increased glutamine metabolism in cancer would suppress ROS levels (through glutathione production) as well as ER stress and promote mTOR activity, ammonia release from glutamine metabolism will vary between cancer types. Glutaminase releases ammonia in catalysing the reaction of glutamine to glutamate, and some cancers process glutamate to α-ketoglutarate via GLUD (releasing another ammonium ion), whereas others use transamination, which does not release ammonia, as was first described by Lehninger[30]. Similarly, SIRT5 desuccinylates and reduces GLS activity, thus reducing ammonia production and autophagy activation[41]. Through the

Hexosamine
A nitrogenous sugar created from a monosaccharide and amino acids that can be used to modify proteins to aid in protein folding and trafficking.

Electron transport chain
A series of transmembrane protein complexes, present on the inner membrane of mitochondria, that transfer electrons via redox reactions to the terminal electron acceptor oxygen, which is reduced with binding of protons to a water molecule. This generates a proton gradient that powers ATP synthase to produce ATP. Premature leakage of electrons to oxygen can lead to production of reactive oxygen species.

Glutathione
A tripeptide (glutamate–cysteine–glycine) that acts as an important antioxidant. The reduced form (GSH) can react with H_2O_2 to form the oxidized form (GSSG).

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.

relative contributions of SIRT5 and GLUD versus transamination, one might speculate that ammonia production downstream of glutamine metabolism could 'tune' autophagy to the specific needs of the tumour cells to maintain organelle turnover, provide nutrients and reduce cell stress.

Divergent paths to α-ketoglutarate

An aspect of glutamine metabolism in cancer that is perhaps under-studied is the consequence of two divergent pathways that convert glutamate to α-ketoglutarate, and the subsequent fate of the nitrogen derived from glutamate (FIG. 7). The different pathways were first identified more than 30 years ago[30], and the field has made much progress on the 'how' and 'what' of GLUD versus aminotransferase use, but not nearly as much progress on the 'when' or the 'why'. Specifically, the field must still address the relative contributions of each pathway to cancer cell physiology, and how the two different pathways are used depending on tissue of origin, proliferation state, cell health or stress, stage of tumour evolution and oncogenotype.

Reactions via GLUD or aminotransferases result in the production of α-ketoglutarate but have different by-products. In addition to α-ketoglutarate and ammonium, GLUD can produce both NADH and NADPH



Figure 6 | **Glutamine controls mTOR activity.** Amino acids stimulate the mTOR pathway, and amino acid pools rely on glutamine to be maintained. Specifically, arginine and leucine are two amino acids that can together almost fully stimulate mTOR complex 1 (mTORC1) through activation of the RAS-related GTPase (RAG) complex, which in turn recruits mTORC1 to the lysosome and stimulates its activity[72,133,216]. Glutamine can contribute to mTORC1 activation by being exchanged for essential amino acids, including leucine, through the large neutral amino acid transporter 1 (LAT1; a heterodimer of SLC7A5 and SLC3A2) antiporter[17]. This RAG-dependent regulation of mTOR is probably dependent on the lysosomal amino acid transporter SLC38A9, which transports glutamine, arginine and leucine as substrates[129,132,133], as well as the leucine sensor sestrin 2 (not shown in the figure)[217,218]. Although the mechanism is not well understood, α-ketoglutarate (α-KG) may regulate RAGB activity and mTOR activation downstream of glutamine metabolism[219]. Several RAG-independent pathways of mTOR regulation by glutamine have also been identified. Glutamine promotes mTOR localization to the lysosome (and thus activity) through the RAS family member ADP ribosylation factor 1 (ARF1) in a poorly understood mechanism, as well as the TTT–RUVBL1/2 complex (not shown in the figure)[128,130]. GLS, kidney-type glutaminase; GLS2, liver-type glutaminase; GLUD, glutamate dehydrogenase.

with different kinetics[114], which support the TCA cycle, bioenergetics, control of ROS levels and lipid synthesis. In contrast, the by-product of aminotransferases is α-ketoglutarate as well as other amino acids such as serine, alanine, aspartate, and asparagine downstream of aspartate, which contribute to several cell functions such as nucleotide biosynthesis, redox control and suppression of the ISR[65,84,85,97,98,139–141]. In breast cancer with genomic amplification of the serine biosynthesis gene phosphoglycerate dehydrogenase (*PHGDH*), PSAT1 is the major source of glutamine-dependent α-ketoglutarate, through transamination, and breast cancer cells with amplified *PHGDH* grow poorly after *PHGDH* depletion compared with those with normal *PHGDH* levels[142], underscoring the importance of these reactions in certain tumour types. Alanine is a product of transamination that is highly secreted from some tumour types[30,141], which perhaps may safely dispose of nitrogen without ammonia production. Although some tumours are sensitive to the aminotransferase inhibitor aminooxyacetate (AOA)[65,143], it is a broad-spectrum inhibitor, and so specific inhibition of individual aminotransferases will be required to assess their specific roles in cancer.

The underlying oncogenotype affects these two pathways differentially, which may be related to the metabolic requirements that the oncogenes impose on the cells. MYC upregulates both GLUD and aminotransferases[144], and seems to require both pathways, depending on the context[67,145]. In contrast, oncogenic mutant KRAS activity increases aminotransferases and decreases GLUD mRNA expression[34]. The role of mTOR in glutamine metabolism seems highly context and cell-type specific: in mouse embryo fibroblasts (MEFs) and colon and prostate cancer cells, mTOR supports increased activity of GLUD via repression of SIRT4 (REFS 69,73,116), whereas in mouse mammary 3D culture models and human breast cancer, mTOR instead inhibits expression of GLUD while promoting expression of aminotransferases, particularly *PSAT1* (REF. 117). It is notable that mTOR requires constant amino acid input[146], whereas KRAS drives macropinocytosis[22], and thus, pathway selection of glutamine catabolism by these two pathways may reflect differing metabolic requirements that we do not yet fully appreciate. Nonetheless, these studies do suggest that transformed cells with strong PI3K–AKT–mTOR, KRAS or MYC pathway activation increase their flux of glutamate to α-ketoglutarate for metabolism and biosynthesis.

Some key differences in the two pathways from glutamate to α-ketoglutarate may warrant further studies. Most noticeably, in addition to ammonia release by GLS, GLUD releases an additional ammonium ion and transamination does not. Although ammonia is often thought of as a toxic by-product, cancers can use ammonia to induce autophagy and neutralize intracellular pH[137,138,147], and GLUD can also produce NADPH[114] to reduce glutathione and lead to lower levels of ROS[114]. Together, these pathways could reduce cell stress and promote survival in some cancers[148]. GLUD catalyses a reaction that is reversible; however, the high K_m for ammonia limits this reaction to deamination of glutamate in most tissues, with the exception of the liver[66,149]. In contrast,

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.



Figure 7 | **Two roads to α-ketoglutarate.** Glutamate can be converted by one of two different pathways into α-ketoglutarate (α-KG), and the choice of which pathway is used is influenced by oncogene input and cell proliferation and metabolic state. GLS, kidney-type glutaminase; GLS2, liver-type glutaminase; GLUD, glutamate dehydrogenase; ISR, integrated stress response; ROS, reactive oxygen species.

aminotransferases are freely reversible, and thus may provide more metabolic plasticity to certain cancer cells that rely on them. Furthermore, GLUD results in disposal of a nitrogen atom in ammonium, whereas aminotransferase supports a much more biosynthetic phenotype that may better support rapidly growing cancer cells. In fact, a recent study[32] suggests that rapidly dividing mammary epithelial cells in culture as well as highly proliferative human breast cancers upregulate aminotransferases and downregulate GLUD expression. The authors show that growing cells incorporate the nitrogen from glutamine into non-essential amino acids for cell growth, whereas this nitrogen would otherwise be disposed of by GLUD activity[32]. This further suggests that which pathway from glutamate to α-ketoglutarate is used is highly dependent on the metabolic, biosynthetic and stress reduction needs of the cell.

Oncogenes and glutamine metabolism

Glutamine metabolism is upregulated by many oncogenic insults and mutations (TABLE 1). This section highlights and expands on some of these. The *MYC* oncogene has perhaps been most associated with upregulated glutamine metabolism. *MYC* is the third most commonly amplified gene in human cancer[150], and the discovery that MYC-transformed cells become dependent on exogenous glutamine helped to drive a resurgence of the interest in glutamine metabolism[6,31]. MYC was found to upregulate glutamine transporters and induce the expression of GLS at the mRNA and protein levels[48,145], and to drive a glutamine-fuelled TCA cycle and glutathione production in hypoxia[151]. Glutamine in MYC-driven cells can be used for *de novo* proline synthesis[82] or production of the oncometabolite 2-hydroxyglutarate in breast cancer[152], although the latter finding has not been independently corroborated. Infection by adenovirus or Kaposi's sarcoma-associated herpesvirus (KSHV) increases both MYC expression and glutamine metabolism[153,154], and in the case of KSHV this may be part of early tumorigenesis that eventually leads to Kaposi's sarcoma. MYC can also mediate the reprogramming of glutamine metabolism downstream of the activation of other oncogenic pathways, including mTOR[155], and crosstalk with HER2 (also known as ERBB2) and the oestrogen receptor in breast cancer[156]. All these findings support the notion that glutaminolysis is a major component of MYC-driven oncogenesis in most settings.

Oncogenic KRAS-driven transformation induces dependence on glutamine metabolism[108,119,157]. However, different KRAS mutations can have different effects; for instance, lung cancer cells harbouring a KRAS-G12V mutation were much less glutamine-dependent than those harbouring a G12C or G12D mutation, although the reasons for this were not clear[158]. In addition to inducing dependence on glutamine-driven nucleotide metabolism[119], mutant KRAS can increase dependence on aminotransferases through downregulation of GLUD and drive increased production of NADPH to regenerate reduced glutathione and control ROS levels[34] (FIG. 5).

Poor vascularization and hypoxia induce the stabilization of HIF1α or HIF2α (REF. 159), which directs glutamine towards biosynthetic fates that do not require oxygen. HIFα stabilization orchestrates a gene expression programme that promotes the conversion of glucose to lactate, driving it away from the TCA cycle[159,160]. Decreased glucose entry into the TCA cycle can be compensated for by glutamine-fuelled production of the TCA cycle intermediate α-ketoglutarate[151]. However, this α-ketoglutarate is largely channelled through reductive carboxylation in certain cell types to produce citrate, acetyl-CoA and lipids[89–91]. By contrast, glutamine is metabolized in human B cell lymphoma model cells cultured in hypoxia largely through forward TCA cycling, with only a minor amount undergoing reductive carboxylation[151]. HIFα stabilization can occur independently of hypoxia in tumours owing to mutations in factors involved in the degradation of HIFα subunits (such as von Hippel–Lindau tumour suppressor (VHL))[159] or through increased translation through mTOR[161], and glutamine itself can also increase HIFα stabilization[162–164]. We suspect that as more genes and tissues are studied, glutamine metabolism will be found to be reprogrammed through modulation of the pathways described above (TABLE 1) and through novel direct mechanisms.

Glutamine metabolism in the clinic

Imaging. Reprogrammed cancer metabolism can be used to image tumours. Glucose-based [^{18}F]fluorodeoxyglucose positron emission tomography (FDG-PET)[165] has been in use for more than three decades to image and stage tumours via their avid uptake of glucose. However, some tissues, particularly the brain, also take up large amounts of glucose, making FDG-PET ineffective in imaging brain tumours[165]. [^{18}F]fluorinated glutamine (specifically, [^{18}F](2S,4R)4-fluoroglutamine (^{18}F-FGln))

2-Hydroxyglutarate (2HG). An α-hydroxy acid sometimes produced at high levels by cancer cells, which structurally resembles α-ketoglutarate and so inhibits α-ketoglutarate-dependent enzymes such as the Jumonji-family histone demethylases. The D-2HG enantiomer is produced downstream of mutant isocitrate dehydrogenase enzymes in glioma and acute myelogenous leukaemia, and the L-2HG enantiomer is produced under hypoxia.

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.

Table 1 | **Influence of oncogenes and tumour suppressor gene loss on glutamine metabolism**

Oncogenic change	Role in glutamine metabolism	Refs
MYC upregulation	Upregulates glutamine metabolism enzymes and transporters	6,31,48,145,177
KRAS mutations	Drives dependence on glutamine metabolism, suppresses GLUD and drives NADPH generation via ME1	34,108,119, 157,158
HIF1α or HIF2α stabilization	Drives reductive carboxylation of glutamine to citrate for lipid production	89–91
HER2 upregulation	Activates glutamine metabolism through MYC and NF-κB	156,220
p53, p63 or p73 activity	Activates GLS2 expression	128,129,134,135
JAK2-V617F mutation	Activates GLS and increases glutamine metabolism	221
mTOR upregulation	Promotes glutamine metabolism via induction of MYC and GLUD or aminotransferases	155,69,73,117
NRF2 activation	Promotes production of glutathione from glutamine	222
TGFβ–WNT upregulation	Promotes SNAIL and DLX2 activation, which upregulate GLS and activates epithelial-to-mesenchymal transition	183
PKCζ loss	Stimulates glutamine metabolism through serine synthesis	223
PTEN loss	Decreased GLS ubiquitylation	224
RB1 loss	Upregulates GLS and SLC1A5 expression	225

GLUD, glutamate dehydrogenase; GLS, kidney-type glutaminase; GLS2, liver-type glutaminase; HIF, hypoxia-inducible factor; JAK2, Janus kinase 2; ME1, malic enzyme 1; NF-κB, nuclear factor-κB; NRF2, nuclear factor, erythroid derived 2, like 2; PKCζ, protein kinase Cζ; *RB1*, retinoblastoma 1; TGFβ, transforming growth factor-β.

was developed as a potential tumour imaging tracer and validated in animal models[166,167], and ^{18}F-FGln PET has since been evaluated clinically and shown promise in the diagnosis of glioma[168]. Importantly, in glioma, ^{18}F-FGln accumulation does not necessarily suggest increased glutamine catabolism, as mouse orthotopic models of glioma and human patient samples show high rates of glutamine accumulation but comparatively low rates of glutamine metabolism[169–171]. Nonetheless, ^{18}F-FGln is a promising new tool in the diagnosis of cancers refractory to the use of FDG, such as glioma, and it will be of interest to determine whether high ^{18}F-FGln uptake in other tumour types is predictive of glutamine dependence and therapeutic response to inhibition of glutamine metabolism.

Therapy. The dependence of cancer cells on glutamine metabolism has made it an attractive anticancer therapeutic target. As detailed in TABLE 2, many classes of compound that target glutamine metabolism, from initial transport in the cell to conversion to α-ketoglutarate, have been examined. Although most of these are still in the preclinical 'tool compound' stage or have been limited by toxicity, allosteric inhibitors of GLS have shown promise in preclinical models of cancer, and one highly potent compound in this class, CB-839, has moved on to clinical trials. A preclinical tool compound inhibitor of GLS is bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide (BPTES)[172], which has been shown to block the growth of cancer cells *in vitro* and of xenografts *in vivo*, and to slow tumour growth and prolong survival in genetically engineered mouse models of cancer[151,173]. CB-839 has shown efficacy against triple-negative breast cancer and haematological malignancies in preclinical studies[53,54], and is currently the subject of several clinical trials.

The transition of glutaminase inhibition to the clinic will be aided by understanding potential inherent or acquired resistance mechanisms. Cancers that depend on GLS2 (REFS 61,64), which is not sensitive to BPTES or CB-839, would be unlikely to respond to such therapy[174]. The expression of pyruvate carboxylase, which can provide carbon to the TCA cycle through its conversion of pyruvate to oxaloacetate, represents a potential mechanism for glutaminase independence[120,175]. Glutamine synthetase (GLUL) expression may also predict glutamine independence and promote BPTES resistance[171,176–178].

Metabolic synthetic lethality and combination therapy. The heterogeneity, varied oncogenotypes and microenvironment of tumours pose considerable challenges to targeted therapies, but the use of combination therapy is a successful paradigm in the treatment of HIV and certain types of cancer. Particularly attractive drug combinations induce synthetic lethality, in which two drugs induce cell death in combination but not individually. Many candidate preclinical synthetic-lethal treatments target pathways or cellular functions that help cancer cells to compensate for the targeting of another pathway or cellular function. The pleiotropic role of glutamine in cellular functions, such as energy production, macromolecular synthesis, mTOR activation and ROS homeostasis[179], makes GLS inhibition a potentially ideal candidate for combination therapy, as detailed in TABLE 3. A few combinations are notable because they reveal novel consequences of glutamine metabolism. Specific inhibition of the anti-apoptotic protein BCL-2 synergizes with glutaminase inhibition[53], consistent with the described role of glutamine in controlling expression and activity of pro-apoptotic and anti-apoptotic proteins, as reviewed recently[180]. Similarly, the synergism between glutamine withdrawal and chemical

Synthetic lethality
An effect in which two inhibitors or losses of function that, individually, do not produce death in cancer cells, if combined, synergistically induce death. Given that cancers may alter their metabolism in response to traditional chemotherapy and targeted agents, metabolic inhibitors such as inhibitors of glutamine metabolism are particularly attractive targets in synthetic lethality studies.

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.

Epithelial-to-mesenchymal transition
(EMT). A complex process observed in invasive solid tumours of epithelial origin in which the cancer cells acquire a mesenchymal phenotype, break through the basement membrane and enter the bloodstream or lymphatic system by the process of intravasation. EMT is promoted by many genetic, epigenetic and physiological alterations commonly found in cancer.

Ferroptosis
An intracellular iron-dependent form of cell death that is distinct from apoptosis.

activation of the ISR with the retinoid derivative fenretinide[65] shows that glutamine can suppress this stress response through various mechanisms, as discussed above. Although invasive and metastatic cells have not specifically been studied for their sensitivity to glutaminolysis inhibition, it has been shown that highly invasive ovarian cancer cells have increased glutamine dependence compared with less invasive cells[181], and metastatic prostate tumours show increased glutamate availability and dependence on glutamine uptake[93,182]. Indeed, genetic inhibition of glutaminase was shown to prevent epithelial-to-mesenchymal transition, a key step in tumour cell invasiveness and eventual metastasis[183]. Thus, prevention of metastasis may be another avenue to focus on in the development of combinatorial strategies in glutamine metabolic inhibition.

The effects of metabolic inhibitors *in vivo* may also broadly influence immunity. There has been a recent surge of interest in manipulating the immune response to target cancer, by either the blockade of immune checkpoints or the use of engineered chimeric antigen receptor (CAR) T cells. These approaches require immune cells to function within the tumour microenvironment. Recent work has indicated that immune cells compete with cancer cells for glucose[184], and we speculate that perhaps this may be true for glutamine as well. In fact, glutamine metabolism is increased in T cell activation and regulates the skewing of $CD4^+$ T cells towards more inflammatory subtypes[32,185,186]. Although *ex vivo* experiments suggest that lymphocytes show signs of proper activation even in the presence of CB-839 (REF. 173), it remains to be seen how GLS inhibition will affect antitumour immunity *in vivo*. Studies in mouse lymphocytes suggest that the CB-839-insensitive GLS2 may have a key role in lymphocyte proliferation[144], and so targeting of glutamine metabolism through the modulation of tumour-specific pathways may be required to maintain both high glutamine availability and immune response.

Glutamine usage: plastic versus patient

Although the crucial role of glutamine metabolism in cancer cells *in vitro* is well established, it is less clear what part glutamine plays in tumours *in vivo*, which can face shortages of nutrients and oxygen[7]. Not surprisingly, tumours use various nutrients as carbon sources and energy besides glucose and glutamine, including lipids and acetate[187–189], and may also use macropinocytosis to support amino acid pools[22]. However, the circumstances under which macropinocytosis becomes dominant *in vivo* remain to be established. As an illustrative example of the metabolic complexity of tumours, lung cancer cell lines are often glutamine dependent *in vitro*, but a recent study of KRAS-driven mouse lung tumours demonstrated that glucose but not glutamine was preferentially used to supply carbon to the TCA cycle, through the action of pyruvate carboxylase[190]. Furthermore, two recent metabolomics and metabolic flux studies of primary human lung cancer showed little change in glutamine entry into the TCA cycle, and instead suggested that human lung cancer can synthesize glutamine from the TCA cycle[120,191]. Human and mouse gliomas exhibit high rates of glucose catabolism and accumulate but do not avidly metabolize glutamine[168], and do not depend on circulating glutamine to maintain cancer growth but instead use glucose to synthesize glutamine through GLUL to support nucleotide biosynthesis[169–171].

Table 2 | **Strategies to pharmacologically target glutamine metabolism in cancer**

Class	Drug	Status
Glutamine mimic	• DON[16] • Azaserine[16] • Acivicin[16]	• Off-target effect on nucleotide biosynthesis[16,226] • Limited by toxicity[16,227]
Glutamine depletion	L-Asparaginase[100,101,228–230]	• Off-target toxic conversion of glutamine to glutamate[231,232] • Limited by toxicity[100,101] • FDA-approved to treat ALL[102]
GLS inhibitors	968 (REF. 233)	Preclinical tool[237]
	BPTES[172,234–236]	Preclinical tool[151,173]
	CB-839 (REFS 53,54)	Phase I clinical trial
SLC1A5 inhibitors	• Benzylserine[238,239] • γ-FBP[240] • GPNA[241]	Preclinical tools[238–241]
GLUD inhibitors	EGCG[242,243]	Tool compound[65,67]
	R162 (REF. 148)	Preclinical tool compound[148]
Aminotransferase inhibitors	AOA[65,143]	• Clinically used to treat tinnitus[244] • Toxic at higher doses[143]
SLC7A11 or xCT system inhibitors	Sulfasalazine[18]	FDA approved for arthritis[18]
	Erastin[245]	Tool compound, induces iron-dependent ferroptosis[246]

ALL, acute lymphoblastic leukaemia; AOA, aminooxyacetate; DON, 6-diazo-5-oxo-l-norleucine; FDA, US Food and Drug Administration; γ-FBP, γ-folate binding protein; GLS, kidney-type glutaminase; GLUD, glutamate dehydrogenase; GPNA, L-γ-glutamyl-*p*-nitroanilide.

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.

Table 3 | **Treatments that are synthetically lethal with inhibition of glutamine metabolism**

Co-treatment	Rationale	Refs
Metformin	Metformin decreases glucose oxidation to increase cellular dependence on glutamine	247
GLUT1 inhibition	Combined downregulation of glucose transport (apigenin) and glutaminase causes severe metabolic stress	248
Glycolysis inhibition (2-DG)	Blockade of compensatory glutamine contribution to TCA cycle, nucleotides and mTOR signalling blocks growth in 2-DG-resistant cells	249
Mitochondrial pyruvate carrier inhibition	Specific chemical inhibition of pyruvate transport into the mitochondrion synergizes with inhibition of glutaminolysis to cause increased death	250
Transglutaminase inhibition	Combined inhibition of glutaminase and transglutaminase causes potentially lethal acidification	251
mTOR inhibition	Consistent with the role of glutamine in mTOR activation and mTOR control of metabolism, GLS and mTOR inhibition are synthetically lethal	219,252
ATF4 activation	Glutamine withdrawal activates the ISR, and further activating this pathway with the retinoid derivative fenretinide causes increased cancer cell death	65
BCL-2 inhibition	Inhibiting GLS causes apoptosis through altered metabolism, with the effect exacerbated by inhibition of the anti-apoptotic protein BCL-2	53
HSP90 inhibition	Consistent with a role of GLS in controlling ROS and ER stress, HSP90 and GLS inhibition cause ER stress-induced cell death via ROS	253
BRAF inhibition	BRAF inhibition resistance causes a shift to glutamine dependence; thus, combination therapy may be used to combat this resistance	254
NOTCH inhibition	NOTCH1 promotes glutaminolysis in T-ALL, sensitizing NOTCH-inhibited T-ALL cells to genetic and pharmacological GLS inhibition	255
EGFR inhibition	GLS inhibition restores sensitivity to the EGFR inhibitor erlotinib in cells that have developed resistance	256

ATF4, activating transcription factor 4; 2-DG, 2-deoxyglucose; EGFR, epidermal growth factor receptor; ER, endoplasmic reticulum; GLS, kidney-type glutaminase; GLUT1, glucose transporter 1; HSP90, heat shock protein 90; ISR, integrated stress response; ROS, reactive oxygen species; T-ALL, T cell acute lymphoblastic leukaemia; TCA, tricarboxylic acid.

Hence, much more work is needed to further define the use of nutrients *in vivo*, to guide the selection of metabolic therapies in the clinic.

Nevertheless, glutamine metabolism has been documented as crucial for tumorigenesis and tumour survival in specific *in vivo* models[151,173,192,193], which have varied metabolic profiles depending on the tumour oncogenotype. The complexities *in vivo* are exemplified by a study using mouse models to compare the effects of metabolic driver and tissue of origin on tumour metabolism[177] (FIG. 8). MET-driven liver tumours expressed GLUL and so presumably made their own glutamine from glucose flux, and thus do not need to take up glutamine from the environment. Likewise, MYC-driven lung tumours upregulated both GLS and GLUL, consistent with a recent study showing that MYC indirectly induces GLUL[177,178]. Conversely, MYC-driven liver tumours upregulated GLS and SLC1A5 and avidly consumed and catabolized glutamine[173,177] (FIG. 8). In fact, in this same MYC-driven liver cancer model, loss of a single copy of *GLS* slowed tumour growth and pharmacological inhibition of GLS prolonged survival[173], suggesting the crucial importance of glutamine metabolism in certain cancer settings. The heterogeneity of glutamine metabolism in tumours arising in the same tissue type, demonstrated by the MYC- and MET-driven liver models, is mirrored in studies of human breast cancer that show that oestrogen receptor-positive breast cancer cell lines are less glutamine dependent than triple-negative breast cancer cell lines[18,54,176]. This finding is further supported by a study in primary oestrogen receptor-negative human breast tumours that shows a high glutamine/glutamate ratio in the tumours, suggesting increased glutamine catabolism[194].

Altered glutamine metabolism can interact with the tumour microenvironment in surprising ways. Increased lactate, which may be present in the microenvironment as a consequence of increased glycolysis by cancer cells[7], has been shown to promote increased glutamine metabolism by a HIF2- and MYC-dependent mechanism[195], potentially providing a way for an evolving tumour to 'reprogramme' itself towards increased glutaminolysis. Similarly, as discussed above, increased glutaminolysis causes an increase in excreted ammonia and autophagy in exposed cells[137,138], and indeed, a study using co-culture of breast cancer cells and fibroblasts showed that the ammonia released from breast cancer cells stimulated autophagy in the fibroblasts to release additional glutamine, which was then taken up and metabolized by the cancer cells[196]. However, ammonia can be toxic to surrounding cells, and as tumours engaging in glutaminolysis may excrete large amounts of ammonia, it is still unknown how surrounding non-transformed cells detoxify this ammonia. Finally, some tumours, particularly those of the brain and the lung[120,169–171,191], may synthesize and excrete glutamine, and it is still not known how this increased glutamine in the microenvironment may affect the physiology of neighbouring

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.



Figure 8 | **Differing requirements for glutamine in cancer based on oncogene and tissue of origin.** The oncoproteins MET and MYC lead to differing dependence on glutamine in different cancer types, which is partially influenced by differential expression of glutamine synthetase (GLUL) or kidney-type glutaminase (GLS). α-KG, α-ketoglutarate; OAA, oxaloacetate. Illustration is drawn from primary data originally presented in Yuneva *et al.*[177].

cells. Understanding the interaction between tumour microenvironment, tissue of origin and oncogenic drivers may be the key to deconvoluting the potential role of glutamine in different tumour types.

Concluding remarks

Ninety years ago, Warburg discovered that many animal and human tumours displayed high avidity for glucose, which was largely converted to lactate through aerobic glycolysis. Warburg also suggested that cancers are caused by altered metabolism and loss of mitochondrial function. These dogmatic views have been replaced and refined over the past several decades with the emergence of oncogenic alterations of metabolism, appreciation of the importance of mitochondrial oxidation in cancer physiology and the rediscovery of the role of glutamine in tumour cell growth in addition to the pivotal role of glucose. In this Review, we provide an updated overview of glutamine metabolism in cancers and discuss the complexity of metabolic rewiring as a function of the tumour oncogenotype as well as the microenvironment, which adds to the heterogeneity found *in vivo*. In certain types of cancer, such as those driven by MYC, tumour cells seem to depend on glutamine, and hence targeting glutamine metabolism pharmacologically may prove beneficial. Conversely, different oncogenic drivers may result in tumour cells that could bypass the need for glutamine. However, targeted inhibition of some oncogenic drivers has been reported to rewire cells to become dependent on glutamine, and hence targeted inhibitors could be synthetically lethal with inhibition of glutamine metabolism. Overall, the field of cancer metabolism has made considerable progress in understanding alternative fuel sources for cancers, including glutamine, which under specific circumstances can be exploited for therapeutic purposes.

1. Warburg, O. On the origin of cancer cells. *Science* **123**, 309–314 (1956).
2. DeBerardinis, R. J. & Cheng, T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. *Oncogene* **29**, 313–324 (2010).
3. Hensley, C. T., Wasti, A. T. & DeBerardinis, R. J. Glutamine and cancer: cell biology, physiology, and clinical opportunities. *J. Clin. Invest.* **123**, 3678–3684 (2013).
4. Lacey, J. M. & Wilmore, D. W. Is glutamine a conditionally essential amino acid? *Nutr. Rev.* **48**, 297–309 (1990).
5. Rubin, A. L. Suppression of transformation by and growth adaptation to low concentrations of glutamine in NIH-3T3 cells. *Cancer Res.* **50**, 2832–2839 (1990).
6. Yuneva, M., Zamboni, N., Oefner, P., Sachidanandam, R. & Lazebnik, Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. *J. Cell Biol.* **178**, 93–105 (2007).
This paper connects MYC transformation to the dependence on glutamine to prevent apoptosis.
7. Mayers, J. R. & Vander Heiden, M. G. Famine versus feast: understanding the metabolism of tumors *in vivo*. *Trends Biochem. Sci.* **40**, 130–140 (2015).
8. Bergstrom, J., Furst, P., Noree, L. O. & Vinnars, E. Intracellular free amino acid concentration in human muscle tissue. *J. Appl. Physiol.* **36**, 693–697 (1974).
9. Krebs, H. A. in *Glutamine: Metabolism, Enzymology, and Regulation* (eds Mora, J. & Palacios, R.) 319–329 (Academic Press, 1980).
10. Stumvoll, M., Perriello, G., Meyer, C. & Gerich, J. Role of glutamine in human carbohydrate metabolism in kidney and other tissues. *Kidney Int.* **55**, 778–792 (1999).
11. Felig, P., Wahren, J. & Raf, L. Evidence of inter-organ amino-acid transport by blood cells in humans. *Proc. Natl Acad. Sci. USA* **70**, 1775–1779 (1973).
12. Taylor, L. & Curthoys, N. P. Glutamine metabolism: role in acid–base balance. *Biochem. Mol. Biol. Educ.* **32**, 291–304 (2004).
13. Krebs, H. A. & Henseleit, K. Untersuchungen uber die Harnstoffbildung im Tierkörper. *Hoppe-Seylers Z. Physiol. Chemie* **210**, 33–66 (1932).
14. Windmueller, H. G. & Spaeth, A. E. Uptake and metabolism of plasma glutamine by the small intestine. *J. Biol. Chem.* **249**, 5070–5079 (1974).
15. Bhutia, Y. D., Babu, E., Ramachandran, S. & Ganapathy, V. Amino acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs. *Cancer Res.* **75**, 1782–1788 (2015).
16. Wise, D. R. & Thompson, C. B. Glutamine addiction: a new therapeutic target in cancer. *Trends Biochem. Sci.* **35**, 427–433 (2010).
17. Nicklin, P. *et al.* Bidirectional transport of amino acids regulates mTOR and autophagy. *Cell* **136**, 521–534 (2009).
This paper establishes the role of glutamine import and then export in exchange for other amino acids in the activation of mTOR.

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.

18. Timmerman, L. A. *et al.* Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. *Cancer Cell* **24**, 450–465 (2013).
This study identifies glutamine metabolism and amino acid exchange as potential targets in treating triple-negative breast cancer.
19. Kerr, M. C. & Teasdale, R. D. Defining macropinocytosis. *Traffic* **10**, 364–371 (2009).
20. Bar-Sagi, D. & Feramisco, J. R. Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. *Science* **233**, 1061–1068 (1986).
21. Kamphorst, J. J. *et al.* Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. *Cancer Res.* **75**, 544–553 (2015).
22. Commisso, C. *et al.* Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. *Nature* **497**, 633–637 (2013).
23. Palm, W. *et al.* The utilization of extracellular proteins as nutrients is suppressed by mTORC1. *Cell* **162**, 259–270 (2015).
24. Overmeyer, J. H., Kaul, A., Johnson, E. E. & Maltese, W. A. Active ras triggers death in glioblastoma cells through hyperstimulation of macropinocytosis. *Mol. Cancer Res.* **6**, 965–977 (2008).
25. Strohecker, A. M. *et al.* Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. *Cancer Discov.* **3**, 1272–1285 (2013).
26. Lin, T. C. *et al.* Autophagy: resetting glutamine-dependent metabolism and oxygen consumption. *Autophagy* **8**, 1477–1493 (2012).
27. Pochini, L., Scalise, M., Galluccio, M. & Indiveri, C. Membrane transporters for the special amino acid glutamine: structure/function relationships and relevance to human health. *Front. Chem.* **2**, 61 (2014).
28. Curthoys, N. P. & Watford, M. Regulation of glutaminase activity and glutamine metabolism. *Annu. Rev. Nutr.* **15**, 133–159 (1995).
29. Krebs, H. A. Metabolism of amino-acids: the synthesis of glutamine from glutamic acid and ammonia, and the enzymic hydrolysis of glutamine in animal tissues. *Biochem. J.* **29**, 1951–1969 (1935).
This paper establishes the existence of glutaminase in mammalian tissues.
30. Moreadith, R. W. & Lehninger, A. L. The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)$^+$-dependent malic enzyme. *J. Biol. Chem.* **259**, 6215–6221 (1984).
This study shows that glutamate can be converted to α-ketoglutarate in cancer cells by either GLUD or aminotransferases, and that the relative contribution of each pathway varies by cell type. It also elucidates the contribution of glutamine-derived malate to the production of NADPH.
31. DeBerardinis, R. J. *et al.* Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. *Proc. Natl Acad. Sci. USA* **104**, 19345–19350 (2007).
This study shows that MYC-mediated transformation drives glutamine into biosynthetic pathways.
32. Wang, R. *et al.* The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. *Immunity* **35**, 871–882 (2011).
33. Fan, J. *et al.* Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. *Mol. Syst. Biol.* **9**, 712 (2013).
34. Son, J. *et al.* Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. *Nature* **496**, 101–105 (2013).
This paper finds that KRAS drives an aminotransferase-dependent glutamine pathway to produce NADPH in pancreatic cancer.
35. Hosios, A. M. *et al.* Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. *Dev. Cell* **36**, 540–549 (2016).
This paper shows that glutamine contributes to biomass accumulation in cancer cells mostly through protein synthesis.
36. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* **348**, 648–660 (2015).
37. Cassago, A. *et al.* Mitochondrial localization and structure-based phosphate activation mechanism of glutaminase C with implications for cancer metabolism. *Proc. Natl Acad. Sci. USA* **109**, 1092–1097 (2012).
38. Elgadi, K. M., Meguid, R. A., Qian, M., Souba, W. W. & Abcouwer, S. F. Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. *Physiol. Genom.* **1**, 51–62 (1999).
39. Shapiro, R. A., Farrell, L., Srinivasan, M. & Curthoys, N. P. Isolation, characterization, and *in vitro* expression of a cDNA that encodes the kidney isoenzyme of the mitochondrial glutaminase. *J. Biol. Chem.* **266**, 18792–18796 (1991).
40. Lu, W., Zuo, Y., Feng, Y. & Zhang, M. SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer. *Tumour Biol.* **35**, 10699–10705 (2014).
41. Polletta, L. *et al.* SIRT5 regulation of ammonia-induced autophagy and mitophagy. *Autophagy* **11**, 253–270 (2015).
42. Hebert, A. S. *et al.* Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. *Mol. Cell* **49**, 186–199 (2013).
43. Zhao, L., Huang, Y. & Zheng, J. STAT1 regulates human glutaminase 1 promoter activity through multiple binding sites in HIV-1 infected macrophages. *PLoS ONE* **8**, e76581 (2013).
44. Masamha, C. P. *et al.* CFIm25 links alternative polyadenylation to glioblastoma tumour suppression. *Nature* **510**, 412–416 (2014).
45. Redis, R. S. *et al.* Allele-specific reprogramming of cancer metabolism by the long non-coding RNA CCAT2. *Mol. Cell* **61**, 520–534 (2016).
46. Ince-Dunn, G. *et al.* Neuronal Elav-like (Hu) proteins regulate RNA splicing and abundance to control glutamate levels and neuronal excitability. *Neuron* **75**, 1067–1080 (2012).
47. Xia, Z. *et al.* Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3′-UTR landscape across seven tumour types. *Nat. Commun.* **5**, 5274 (2014).
48. Gao, P. *et al.* c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. *Nature* **458**, 762–765 (2009).
This study shows that MYC downregulation of mir-23a/b relieves repression of *GLS* as part of the oncogenic reprogramming of glutamine metabolism.
49. Hansen, W. R., Barsic-Tress, N., Taylor, L. & Curthoys, N. P. The 3′-nontranslated region of rat renal glutaminase mRNA contains a pH-responsive stability element. *Am. J. Physiol.* **271**, F126–F131 (1996).
50. Colombo, S. L. *et al.* Anaphase-promoting complex/cyclosome-Cdh1 coordinates glycolysis and glutaminolysis with transition to S phase in human T lymphocytes. *Proc. Natl Acad. Sci. USA* **107**, 18868–18873 (2010).
51. Colombo, S. L. *et al.* Molecular basis for the differential use of glucose and glutamine in cell proliferation as revealed by synchronized HeLa cells. *Proc. Natl Acad. Sci. USA* **108**, 21069–21074 (2011).
52. van den Heuvel, A. P., Jing, J., Wooster, R. F. & Bachman, K. E. Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth. *Cancer Biol. Ther.* **13**, 1185–1194 (2012).
53. Jacque, N. *et al.* Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. *Blood* **126**, 1346–1356 (2015).
54. Gross, M. I. *et al.* Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. *Mol. Cancer Ther.* **13**, 890–901 (2014).
55. Suzuki, S. *et al.* Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. *Proc. Natl Acad. Sci. USA* **107**, 7461–7466 (2010).
56. Hu, W. *et al.* Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. *Proc. Natl Acad. Sci. USA* **107**, 7455–7460 (2010).
57. Zhang, J. *et al.* Epigenetic silencing of glutaminase 2 in human liver and colon cancers. *BMC Cancer* **13**, 601 (2013).
58. Liu, J. *et al.* Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. *Oncotarget* **5**, 2635–2647 (2014).
59. Szeliga, M., Bogacinska-Karas, M., Kuzmicz, K., Rola, R. & Albrecht, J. Downregulation of GLS2 in glioblastoma cells is related to DNA hypermethylation but not to the p53 status. *Mol. Carcinog.* https://dx.doi.org/10.1002/mc.22372 (2015).
60. Zhang, C. *et al.* Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis. *Elife* **5**, e10727 (2016).
61. Xiang, L. *et al.* Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation. *Biochim. Biophys. Acta* **1833**, 2996–3005 (2013).
62. Velletri, T. *et al.* GLS2 is transcriptionally regulated by p73 and contributes to neuronal differentiation. *Cell Cycle* **12**, 3564–3573 (2013).
63. Giacobbe, A. *et al.* p63 regulates glutaminase 2 expression. *Cell Cycle* **12**, 1395–1405 (2013).
64. Xiao, D. *et al.* Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2. *Oncotarget* **6**, 40655–40666 (2015).
65. Qing, G. *et al.* ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. *Cancer Cell* **22**, 631–644 (2012).
66. Treberg, J. R., Brosnan, M. E., Watford, M. & Brosnan, J. T. On the reversibility of glutamate dehydrogenase and the source of hyperammonemia in the hyperinsulinism/hyperammonemia syndrome. *Adv. Enzyme Regul.* **50**, 34–43 (2010).
67. Yang, C. *et al.* Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. *Cancer Res.* **69**, 7986–7993 (2009).
68. Fahien, L. A. & Kmiotek, E. Regulation of glutamate dehydrogenase by palmitoyl-coenzyme A. *Arch. Biochem. Biophys.* **212**, 247–253 (1981).
69. Haigis, M. C. *et al.* SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. *Cell* **126**, 941–954 (2006).
70. Frieden, C. Glutamate dehydrogenase v. the relation of enzyme structure to catalytic function. *J. Biol. Chem.* **238**, 3286–3299 (1963).
71. Li, M., Li, C., Allen, A., Stanley, C. A. & Smith, T. J. The structure and allosteric regulation of mammalian glutamate dehydrogenase. *Arch. Biochem. Biophys.* **519**, 69–80 (2012).
72. Sancak, Y. *et al.* The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. *Science* **320**, 1496–1501 (2008).
73. Csibi, A. *et al.* The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. *Cell* **153**, 840–854 (2013).
74. Erecinska, M. & Nelson, D. Activation of glutamate dehydrogenase by leucine and its nonmetabolizable analogue in rat brain synaptosomes. *J. Neurochem.* **54**, 1335–1343 (1990).
75. Sorbi, D., Boynton, J. & Lindor, K. D. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. *Am. J. Gastroenterol.* **94**, 1018–1022 (1999).
76. Wroblewski, F. & Ladue, J. S. Serum glutamic pyruvic transaminase in cardiac with hepatic disease. *Proc. Soc. Exp. Biol. Med.* **91**, 569–571 (1956).
77. Vroon, D. H. & Israili, Z. in *Clinical Methods: The History, Physical, and Laboratory Examinations* (eds Walker, H. K., Hall, W. D. & Hurst, J. W.) (Butterworths, 1990).
78. Awapara, J. & Seale, B. Distribution of transaminases in rat organs. *J. Biol. Chem.* **194**, 497–502 (1952).
79. Snell, K. Enzymes of serine metabolism in normal, developing and neoplastic rat tissues. *Adv. Enzyme Regul.* **22**, 325–400 (1984).
80. Phang, J. M., Liu, W., Hancock, C. N. & Fischer, J. W. Proline metabolism and cancer: emerging links to glutamine and collagen. *Curr. Opin. Clin. Nutr. Metab. Care* **18**, 71–77 (2015).
81. Liu, W. & Phang, J. M. Proline dehydrogenase (oxidase) in cancer. *Biofactors* **38**, 398–406 (2012).
82. Liu, W. *et al.* Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. *Proc. Natl Acad. Sci. USA* **109**, 8983–8988 (2012).
83. Alberghina, L. & Gaglio, D. Redox control of glutamine utilization in cancer. *Cell Death Dis.* **5**, e1561 (2014).
84. Sullivan, L. B. *et al.* Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. *Cell* **162**, 552–563 (2015).

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.

85. Birsoy, K. *et al.* An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. *Cell* **162**, 540–551 (2015).
86. Patel, D. *et al.* Aspartate rescues s-phase arrest caused by suppression of glutamine utilization in KRas-driven cancer cells. *J. Biol. Chem.* **291**, 9322–9329 (2016).
87. Ward, P. S. *et al.* The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell* **17**, 225–234 (2010).
88. Fan, J., Kamphorst, J. J., Rabinowitz, J. D. & Shlomi, T. Fatty acid labeling from glutamine in hypoxia can be explained by isotope exchange without net reductive isocitrate dehydrogenase (IDH) flux. *J. Biol. Chem.* **288**, 31363–31369 (2013).
89. Gameiro, P. A. *et al. In vivo* HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. *Cell Metab.* **17**, 372–385 (2013).
90. Wise, D. R. *et al.* Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. *Proc. Natl Acad. Sci. USA* **108**, 19611–19616 (2011).
This study describes the reverse flux of glutamine through IDH to citrate in a HIF-dependent manner.
91. Metallo, C. M. *et al.* Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. *Nature* **481**, 380–384 (2012).
This paper describes the reverse flux of glutamine through IDH to lipid synthesis in hypoxia.
92. Mullen, A. R. *et al.* Reductive carboxylation supports growth in tumour cells with defective mitochondria. *Nature* **481**, 385–388 (2012).
93. Dasgupta, S. *et al.* Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. *J. Clin. Invest.* **125**, 1174–1188 (2015).
94. Sun, R. C. & Denko, N. C. Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. *Cell Metab.* **19**, 285–292 (2014).
95. Jiang, L. *et al.* Reductive carboxylation supports redox homeostasis during anchorage-independent growth. *Nature* **532**, 255–258 (2016).
96. Harding, H. P. *et al.* An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. *Mol. Cell* **11**, 619–633 (2003).
97. Ye, J. *et al.* The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. *EMBO J.* **29**, 2082–2096 (2010).
98. Zhang, J. *et al.* Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. *Mol. Cell* **56**, 205–218 (2014).
99. Bunpo, P. *et al.* GCN2 protein kinase is required to activate amino acid deprivation responses in mice treated with the anti-cancer agent L-asparaginase. *J. Biol. Chem.* **284**, 32742–32749 (2009).
100. Broome, J. D. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. *J. Exp. Med.* **118**, 99–120 (1963).
101. Oettgen, H. F. *et al.* Inhibition of leukemias in man by L-asparaginase. *Cancer Res.* **27**, 2619–2631 (1967).
102. Pui, C.-H. & Evans, W. E. Treatment of acute lymphoblastic leukemia. *N. Engl. J. Med.* **354**, 166–178 (2006).
103. Sodi, V. L. *et al.* mTOR/MYC axis regulates O-GlcNAc transferase expression and O-GlcNAcylation in breast cancer. *Mol. Cancer Res.* **13**, 923–933 (2015).
104. Shi, Y. *et al.* Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia. *Leukemia* **24**, 1588–1598 (2010).
105. Lynch, T. P. *et al.* Critical role of O-linked β-*N*-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. *J. Biol. Chem.* **287**, 11070–11081 (2012).
106. Zachara, N. E. *et al.* Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells. *J. Biol. Chem.* **279**, 30133–30142 (2004).
107. Housley, M. P. *et al.* O-GlcNAc regulates FoxO activation in response to glucose. *J. Biol. Chem.* **283**, 16283–16292 (2008).
108. Weinberg, F. *et al.* Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. *Proc. Natl Acad. Sci. USA* **107**, 8788–8793 (2010).
109. Hamanaka, R. B. & Chandel, N. S. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. *Trends Biochem. Sci.* **35**, 505–513 (2010).
110. Welbourne, T. C. Ammonia production and glutamine incorporation into glutathione in the functioning rat kidney. *Can. J. Biochem.* **57**, 233–237 (1979).
111. Godwin, A. K. *et al.* High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. *Proc. Natl Acad. Sci. USA* **89**, 3070–3074 (1992).
112. Rubio, I. *et al.* Oral glutamine reduces radiation morbidity in breast conservation surgery. *JPEN J. Parenter. Enteral Nutr.* **37**, 623–630 (2013).
113. Cao, Y., Kennedy, R. & Klimberg, V. S. Glutamine protects against doxorubicin-induced cardiotoxicity. *J. Surg. Res.* **85**, 178–182 (1999).
114. Botman, D., Tigchelaar, W. & Van Noorden, C. J. Determination of glutamate dehydrogenase activity and its kinetics in mouse tissues using metabolic mapping (quantitative enzyme histochemistry). *J. Histochem. Cytochem.* **62**, 802–812 (2014).
115. Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. *Cell* **149**, 274–293 (2012).
116. Jeong, S. M. *et al.* SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. *Cancer Cell* **23**, 450–463 (2013).
117. Coloff, J. L. *et al.* Differential glutamate metabolism in proliferating and quiescent mammary epithelial cells. *Cell Metab.* **23**, 867–880 (2016).
This paper demonstrates that growing mammary epithelial 3D cultures, as well as highly proliferative human breast cancers, rely on aminotransferases downstream of glutamine metabolism for biosynthesis, whereas quiescent cells instead express GLUD.
118. Lane, A. N. & Fan, T. W. Regulation of mammalian nucleotide metabolism and biosynthesis. *Nucleic Acids Res.* **43**, 2466–2485 (2015).
119. Gaglio, D., Soldati, C., Vanoni, M., Alberghina, L. & Chiaradonna, F. Glutamine deprivation induces abortive S-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. *PLoS ONE* **4**, e4715 (2009).
120. Sellers, K. *et al.* Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. *J. Clin. Invest.* **125**, 687–698 (2015).
121. Ben-Sahra, I., Howell, J. J., Asara, J. M. & Manning, B. D. Stimulation of *de novo* pyrimidine synthesis by growth signaling through mTOR and S6K1. *Science* **339**, 1323–1328 (2013).
122. Robitaille, A. M. *et al.* Quantitative phosphoproteomics reveal mTORC1 activates *de novo* pyrimidine synthesis. *Science* **339**, 1320–1323 (2013).
123. Mathew, R. *et al.* Autophagy suppresses tumorigenesis through elimination of p62. *Cell* **137**, 1062–1075 (2009).
124. Takamura, A. *et al.* Autophagy-deficient mice develop multiple liver tumors. *Genes Dev.* **25**, 795–800 (2011).
125. Altman, B. J. *et al.* Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis. *Oncogene* **30**, 1855–1867 (2011).
126. Guo, J. Y. *et al.* Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. *Genes Dev.* **25**, 460–470 (2011).
127. Yorimitsu, T., Nair, U., Yang, Z. & Klionsky, D. J. Endoplasmic reticulum stress triggers autophagy. *J. Biol. Chem.* **281**, 30299–30304 (2006).
128. Jewell, J. L. *et al.* Metabolism. Differential regulation of mTORC1 by leucine and glutamine. *Science* **347**, 194–198 (2015).
129. Jung, J., Genau, H. M. & Behrends, C. Amino acid-dependent mTORC1 regulation by the lysosomal membrane protein SLC38A9. *Mol. Cell. Biol.* **35**, 2479–2494 (2015).
130. Kim, S. G. *et al.* Metabolic stress controls mTORC1 lysosomal localization and dimerization by regulating the TTT-RUVBL1/2 complex. *Mol. Cell* **49**, 172–185 (2013).
131. Palmieri, M. *et al.* Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. *Hum. Mol. Genet.* **20**, 3852–3866 (2011).
132. Rebsamen, M. *et al.* SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. *Nature* **519**, 477–481 (2015).
133. Wang, S. *et al.* Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. *Science* **347**, 188–194 (2015).
134. Settembre, C. *et al.* A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. *EMBO J.* **31**, 1095–1108 (2012).
135. Dunlop, E. A. & Tee, A. R. mTOR and autophagy: a dynamic relationship governed by nutrients and energy. *Semin. Cell Dev. Biol.* **36**, 121–129 (2014).
136. Dewaele, M., Maes, H. & Agostinis, P. ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy. *Autophagy* **6**, 838–854 (2010).
137. Cheong, H., Lindsten, T., Wu, J., Lu, C. & Thompson, C. B. Ammonia-induced autophagy is independent of ULK1/ULK2 kinases. *Proc. Natl Acad. Sci. USA* **108**, 11121–11126 (2011).
138. Eng, C. H., Yu, K., Lucas, J., White, E. & Abraham, R. T. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. *Sci. Signal.* **3**, ra31 (2010).
139. Locasale, J. W. Serine, glycine and one-carbon units: cancer metabolism in full circle. *Nat. Rev. Cancer* **13**, 572–583 (2013).
140. Ye, J. *et al.* Serine catabolism regulates mitochondrial redox control during hypoxia. *Cancer Discov.* **4**, 1406–1417 (2014).
141. Tessem, M. B. *et al.* Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. *Magn. Reson. Med.* **60**, 510–516 (2008).
142. Possemato, R. *et al.* Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. *Nature* **476**, 346–350 (2011).
143. Korangath, P. *et al.* Targeting glutamine metabolism in breast cancer with aminooxyacetate. *Clin. Cancer Res.* **21**, 3263–3273 (2015).
144. Wang, R. *et al.* The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. *Immunity* **35**, 871–882 (2011).
145. Wise, D. R. *et al.* Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. *Proc. Natl Acad. Sci. USA* **105**, 18782–18787 (2008).
This study finds that MYC regulates key glutamine metabolism genes.
146. Wullschleger, S., Loewith, R. & Hall, M. N. TOR signaling in growth and metabolism. *Cell* **124**, 471–484 (2006).
147. Huang, W. *et al.* A proposed role for glutamine in cancer cell growth through acid resistance. *Cell Res.* **23**, 724–727 (2013).
148. Jin, L. *et al.* Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. *Cancer Cell* **27**, 257–270 (2015).
149. Zaganas, I. *et al.* The effect of pH and ADP on ammonia affinity for human glutamate dehydrogenases. *Metab. Brain Dis.* **28**, 127–131 (2013).
150. Zack, T. I. *et al.* Pan-cancer patterns of somatic copy number alteration. *Nat. Genet.* **45**, 1134–1140 (2013).
151. Le, A. *et al.* Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. *Cell Metab.* **15**, 110–121 (2012).
This study documents metabolic rewiring to glutaminolysis under glucose deprivation.
152. Terunuma, A. *et al.* MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. *J. Clin. Invest.* **124**, 398–412 (2014).
153. Thai, M. *et al.* MYC-induced reprogramming of glutamine catabolism supports optimal virus replication. *Nat. Commun.* **6**, 8873 (2015).
154. Sanchez, E. L., Carroll, P. A., Thalhofer, A. B. & Lagunoff, M. Latent KSHV infected endothelial cells are glutamine addicted and require glutaminolysis for survival. *PLoS Pathog.* **11**, e1005052 (2015).
155. Csibi, A. *et al.* The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation. *Curr. Biol.* **24**, 2274–2280 (2014).
156. Chen, Z., Wang, Y., Warden, C. & Chen, S. Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells. *J. Steroid Biochem. Mol. Biol.* **149**, 118–127 (2015).
157. Gaglio, D. *et al.* Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. *Mol. Syst. Biol.* **7**, 523 (2011).
158. Brunelli, L., Caiola, E., Marabese, M., Broggini, M. & Pastorelli, R. Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells. *Oncotarget* **5**, 4722–4731 (2014).

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.

159. Semenza, G. L. Hypoxia-inducible factors in physiology and medicine. *Cell* **148**, 399–408 (2012).
160. Kim, J. W., Tchernyshyov, I., Semenza, G. L. & Dang, C. V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. *Cell Metab.* **3**, 177–185 (2006).
161. Keith, B., Johnson, R. S. & Simon, M. C. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. *Nat. Rev. Cancer* **12**, 9–22 (2012).
162. Drogat, B. *et al.* Acute L-glutamine deprivation compromises VEGF-a upregulation in A549/8 human carcinoma cells. *J. Cell. Physiol.* **212**, 463–472 (2007).
163. Kwon, S. J. & Lee, Y. J. Effect of low glutamine/glucose on hypoxia-induced elevation of hypoxia-inducible factor-1alpha in human pancreatic cancer MiaPaCa-2 and human prostatic cancer DU-145 cells. *Clin. Cancer Res.* **11**, 4694–4700 (2005).
164. Zhdanov, A. V., Waters, A. H., Golubeva, A. V. & Papkovsky, D. B. Differential contribution of key metabolic substrates and cellular oxygen in HIF signalling. *Exp. Cell Res.* **330**, 13–28 (2015).
165. Kelloff, G. J. *et al.* Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. *Clin. Cancer Res.* **11**, 2785–2808 (2005).
166. Ploessl, K., Wang, L., Lieberman, B. P., Qu, W. & Kung, H. F. Comparative evaluation of 18F-labeled glutamic acid and glutamine as tumor metabolic imaging agents. *J. Nucl. Med.* **53**, 1616–1624 (2012).
167. Lieberman, B. P. *et al.* PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. *J. Nucl. Med.* **52**, 1947–1955 (2011).
168. Venneti, S. *et al.* Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas *in vivo*. *Sci. Transl Med.* **7**, 274ra17 (2015).
This paper validates the use of labelled glutamine in the imaging of human gliomas.
169. Choi, C. *et al.* A comparative study of short- and long-TE (1)H MRS at 3 T for *in vivo* detection of 2-hydroxyglutarate in brain tumors. *NMR Biomed.* **26**, 1242–1250 (2013).
170. Marin-Valencia, I. *et al.* Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain *in vivo*. *Cell Metab.* **15**, 827–837 (2012).
171. Tardito, S. *et al.* Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. *Nat. Cell Biol.* **17**, 1556–1568 (2015).
172. Robinson, M. M. *et al.* Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylaceta mido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). *Biochem. J.* **406**, 407–414 (2007).
This paper describes an allosteric inhibitor of GLS.
173. Xiang, Y. *et al.* Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. *J. Clin. Invest.* **125**, 2293–2306 (2015).
This paper provides *in vivo* genetic and pharmacological evidence for the role of *Gls* in MYC-induced mouse liver cancer.
174. Allen, E. *et al.* Metabolic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR signaling. *Cell Rep.* **15**, 1144–1160 (2016).
175. Cheng, T. *et al.* Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. *Proc. Natl Acad. Sci. USA* **108**, 8674–8679 (2011).
176. Kung, H. N., Marks, J. R. & Chi, J. T. Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. *PLoS Genet.* **7**, e1002229 (2011).
177. Yuneva, M. O. *et al.* The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. *Cell Metab.* **15**, 157–170 (2012).
This study shows that tumour tissue of origin and oncogenic drivers combine to regulate glutamine metabolism.
178. Bott, A. J. *et al.* Oncogenic Myc induces expression of glutamine synthetase through promoter demethylation. *Cell Metab.* **22**, 1068–1077 (2015).
179. Chakrabarti, G. *et al.* Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ss-lapachone. *Cancer Metab.* **3**, 12 (2015).
180. Chen, L. & Cui, H. Targeting glutamine induces apoptosis: a cancer therapy approach. *Int. J. Mol. Sci.* **16**, 22830–22855 (2015).
181. Yang, L. *et al.* Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. *Mol. Syst. Biol.* **10**, 728 (2014).
182. Wang, Q. *et al.* Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. *J. Pathol.* **236**, 278–289 (2015).
183. Lee, S. Y. *et al.* Dlx-2 and glutaminase upregulate epithelial-mesenchymal transition and glycolytic switch. *Oncotarget* **7**, 7925–7939 (2016).
184. Chang, C. H. *et al.* Metabolic competition in the tumor microenvironment is a driver of cancer progression. *Cell* **162**, 1229–1241 (2015).
185. Gerriets, V. A. *et al.* Metabolic programming and PDHK1 control $CD4^+$ T cell subsets and inflammation. *J. Clin. Invest.* **125**, 194–207 (2015).
186. Klysz, D. *et al.* Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. *Sci. Signal.* **8**, ra97 (2015).
187. Kamphorst, J. J. *et al.* Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. *Proc. Natl Acad. Sci. USA* **110**, 8882–8887 (2013).
188. Mashimo, T. *et al.* Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. *Cell* **159**, 1603–1614 (2014).
189. Comerford, S. A. *et al.* Acetate dependence of tumors. *Cell* **159**, 1591–1602 (2014).
190. Davidson, S. M. *et al.* Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. *Cell Metab.* **23**, 517–528 (2016).
This paper shows that KRAS-driven lung cancers, although reliant on glutamine *in vitro*, consume far less glutamine *in vivo* and instead use pyruvate carboxylation to add carbon to the TCA cycle.
191. Hensley, C. T. *et al.* Metabolic heterogeneity in human lung tumors. *Cell* **164**, 681–694 (2016).
192. Qing, G. *et al.* Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1α. *Cancer Res.* **70**, 10351–10361 (2010).
193. Shroff, E. H. *et al.* MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. *Proc. Natl Acad. Sci. USA* **112**, 6539–6544 (2015).
194. Budczies, J. *et al.* Glutamate enrichment as new diagnostic opportunity in breast cancer. *Int. J. Cancer* **136**, 1619–1628 (2015).
195. Perez-Escuredo, J. *et al.* Lactate promotes glutamine uptake and metabolism in oxidative cancer cells. *Cell Cycle* **15**, 72–83 (2016).
196. Ko, Y. H. *et al.* Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance. *Cancer Biol. Ther.* **12**, 1085–1097 (2011).
197. Van Slyke, D. D. *et al.* Glutamine as source material of urinary ammonia. *J. Biol. Chem.* **150**, 481–482 (1943).
198. Eagle, H., Oyama, V. I., Levy, M., Horton, C. L. & Fleischman, R. The growth response of mammalian cells in tissue culture to L-glutamine and L-glutamic acid. *J. Biol. Chem.* **218**, 607–616 (1956).
199. Klingman, J. D. & Handler, P. Partial purification and properties of renal glutaminase. *J. Biol. Chem.* **232**, 369–380 (1958).
200. Eagle, H. Nutrition needs of mammalian cells in tissue culture. *Science* **122**, 501–514 (1955).
201. Kovacevic, Z. & Morris, H. P. The role of glutamine in the oxidative metabolism of malignant cells. *Cancer Res.* **32**, 326–333 (1972).
202. Lavietes, B. B., Regan, D. H. & Demopoulos, H. B. Glutamate oxidation of 6C3HED lymphoma: effects of L-asparaginase on sensitive and resistant lines. *Proc. Natl Acad. Sci. USA* **71**, 3993–3997 (1974).
203. Reitzer, L. J., Wice, B. M. & Kennell, D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. *J. Biol. Chem.* **254**, 2669–2676 (1979).
This paper was one of the first to show that glutamine is an important contributor to the TCA cycle in cancer cell lines.
204. Ardawi, M. S. & Newsholme, E. A. Glutamine metabolism in lymphocytes of the rat. *Biochem. J.* **212**, 835–842 (1983).
205. Newsholme, E. A., Crabtree, B. & Ardawi, M. S. The role of high rates of glycolysis and glutamine utilization in rapidly dividing cells. *Biosci. Rep.* **5**, 393–400 (1985).
206. Flier, J. S., Mueckler, M. M., Usher, P. & Lodish, H. F. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. *Science* **235**, 1492–1495 (1987).
207. Rathmell, J. C. *et al.* Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. *Mol. Cell. Biol.* **23**, 7315–7328 (2003).
208. Shim, H. *et al.* c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. *Proc. Natl Acad. Sci. USA* **94**, 6658–6663 (1997).
209. Lobo, C. *et al.* Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. *Biochem. J.* **348**, 257–261 (2000).
210. Wellen, K. E. *et al.* The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. *Genes Dev.* **24**, 2784–2799 (2010).
211. Yelamanchi, S. D. *et al.* A pathway map of glutamate metabolism. *J. Cell Commun. Signal.* **10**, 69–75 (2016).
212. Ishimoto, T. *et al.* CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. *Cancer Cell* **19**, 387–400 (2011).
213. Yang, M. & Vousden, K. H. Serine and one carbon metabolism in cancer. *Nat. Rev. Cancer* in the press (2016).
214. Wek, R. C., Ramirez, M., Jackson, B. M. & Hinnebusch, A. G. Identification of positive-acting domains in GCN2 protein kinase required for translational activation of GCN4 expression. *Mol. Cell. Biol.* **10**, 2820–2831 (1990).
215. Sood, R., Porter, A. C., Olsen, D. A., Cavener, D. R. & Wek, R. C. A mammalian homologue of GCN2 protein kinase important for translational control by phosphorylation of eukaryotic initiation factor-2α. *Genetics* **154**, 787–801 (2000).
216. Chantranupong, L. *et al.* The CASTOR proteins are arginine sensors for the mTORC1 pathway. *Cell* **165**, 153–164 (2016).
217. Ye, J. *et al.* GCN2 sustains mTORC1 suppression upon amino acid deprivation by inducing Sestrin2. *Genes Dev.* **29**, 2331–2336 (2015).
218. Wolfson, R. L. *et al.* Sestrin2 is a leucine sensor for the mTORC1 pathway. *Science* **351**, 43–48 (2016).
219. Duran, R. V. *et al.* Glutaminolysis activates Rag-mTORC1 signaling. *Mol. Cell* **47**, 349–358 (2012).
220. Qie, S., Chu, C., Li, W., Wang, C. & Sang, N. ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation. *J. Cell Biochem.* **115**, 498–509 (2014).
221. Zhan, H., Ciano, K., Dong, K. & Zucker, S. Targeting glutamine metabolism in myeloproliferative neoplasms. *Blood Cells Mol. Dis.* **55**, 241–247 (2015).
222. Mitsuishi, Y. *et al.* Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. *Cancer Cell* **22**, 66–79 (2012).
223. Ma, L. *et al.* Control of nutrient stress-induced metabolic reprogramming by PKCζ in tumorigenesis. *Cell* **152**, 599–611 (2013).
224. Garcia-Cao, I. *et al.* Systemic elevation of PTEN induces a tumor-suppressive metabolic state. *Cell* **149**, 49–62 (2012).
225. Reynolds, M. R. *et al.* Control of glutamine metabolism by the tumor suppressor Rb. *Oncogene* **33**, 556–566 (2014).
226. Griffiths, M., Keast, D., Patrick, G., Crawford, M. & Palmer, T. N. The role of glutamine and glucose analogues in metabolic inhibition of human myeloid leukaemia *in vitro*. *Int. J. Biochem.* **25**, 1749–1755 (1993).
227. Earhart, R. H., Koeller, J. M. & Davis, H. L. Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses. *Cancer Treat. Rep.* **66**, 1215–1217 (1982).
228. Parmentier, J. H. *et al.* Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines. *Leuk. Res.* **39**, 757–762 (2015).
229. Willems, L. *et al.* Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. *Blood* **122**, 3521–3532 (2013).
230. Chan, W. K. *et al.* The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells. *Blood* **123**, 3596–3606 (2014).
231. Reinert, R. B. *et al.* Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. *J. Biol. Chem.* **281**, 31222–31233 (2006).
232. Ollenschlager, G. *et al.* Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. *Eur. J. Clin. Invest.* **18**, 512–516 (1988).

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.

233. Wang, J. B. *et al.* Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. *Cancer Cell* **18**, 207–219 (2010).
234. DeLaBarre, B. *et al.* Full-length human glutaminase in complex with an allosteric inhibitor. *Biochemistry* **50**, 10764–10770 (2011).
235. Ferreira, A. P. *et al.* Active glutaminase C self-assembles into a supratetrameric oligomer that can be disrupted by an allosteric inhibitor. *J. Biol. Chem.* **288**, 28009–28020 (2013).
236. Hartwick, E. W. & Curthoys, N. P. BPTES inhibition of hGA(124-551), a truncated form of human kidney-type glutaminase. *J. Enzyme Inhib Med. Chem.* **27**, 861–867 (2012).
237. Stalnecker, C. A. *et al.* Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells. *Proc. Natl Acad. Sci. USA* **112**, 394–399 (2015).
238. Grewer, C. & Grabsch, E. New inhibitors for the neutral amino acid transporter ASCT2 reveal its Na^+-dependent anion leak. *J. Physiol.* **557**, 747–759 (2004).
239. Wang, Q. *et al.* Targeting glutamine transport to suppress melanoma cell growth. *Int. J. Cancer* **135**, 1060–1071 (2014).
240. Colas, C. *et al.* Ligand discovery for the alanine-serine-cysteine transporter (ASCT2, SLC1A5) from homology modeling and virtual screening. *PLoS Comput. Biol.* **11**, e1004477 (2015).
241. Esslinger, C. S., Cybulski, K. A. & Rhoderick, J. F. Nγ-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site. *Bioorg. Med. Chem.* **13**, 1111–1118 (2005).
242. Li, C. *et al.* Green tea polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase. *J. Biol. Chem.* **281**, 10214–10221 (2006).
243. Li, C. *et al.* Green tea polyphenols control dysregulated glutamate dehydrogenase in transgenic mice by hijacking the ADP activation site. *J. Biol. Chem.* **286**, 34164–34174 (2011).
244. Guth, P. S. *et al.* Evaluation of amino-oxyacetic acid as a palliative in tinnitus. *Ann. Otol. Rhinol. Laryngol.* **99**, 74–79 (1990).
245. Dixon, S. J. *et al.* Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell* **149**, 1060–1072 (2012).
246. Dixon, S. J. *et al.* Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. *Elife* **3**, e02523 (2014).
247. Fendt, S. M. *et al.* Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. *Cancer Res.* **73**, 4429–4438 (2013).
248. Lee, Y. M. *et al.* Inhibition of glutamine utilization sensitizes lung cancer cells to apigenin-induced apoptosis resulting from metabolic and oxidative stress. *Int. J. Oncol.* **48**, 399–408 (2016).
249. Pusapati, R. V. *et al.* mTORC1-dependent metabolic reprogramming underlies escape from glycolysis addiction in cancer cells. *Cancer Cell* **29**, 548–562 (2016).
250. Yang, C. *et al.* Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. *Mol. Cell* **56**, 414–424 (2014).
251. Katt, W. P., Antonyak, M. A. & Cerione, R. A. Simultaneously targeting tissue transglutaminase and kidney type glutaminase sensitizes cancer cells to acid toxicity and offers new opportunities for therapeutic intervention. *Mol. Pharm.* **12**, 46–55 (2015).
252. Tanaka, K. *et al.* Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. *J. Clin. Invest.* **125**, 1591–1602 (2015).
253. Li, J. *et al.* Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells. *Proc. Natl Acad. Sci. USA* **112**, E21–E29 (2015).
254. Hernandez-Davies, J. E. *et al.* Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. *J. Transl Med.* **13**, 210 (2015).
255. Herranz, D. *et al.* Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. *Nat. Med.* **21**, 1182–1189 (2015).
256. Xie, C. *et al.* Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer. *Oncotarget* **7**, 610–621 (2016).

Acknowledgements

The authors thank R. DeBerardinis (Children's Research Institute at University of Texas Southwestern, Dallas, USA) and J. Coloff (Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA) for helpful commentary and discussion. They apologize to any authors whose work could not be included owing to space limitations. This work is partially supported by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) (R01CA057341 (C.V.D)), The Leukemia and Lymphoma Society LLS 6106-14 (C.V.D.) and the Abramson Family Cancer Research Institute. B.J.A. and Z.E.S. were supported by the NCI (F32CA180370 and F32CA174148, respectively).

Competing interests statement

The authors declare no competing interests.

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.

CORRIGENDUM

From Krebs to clinic: glutamine metabolism to cancer therapy

Brian J. Altman, Zachary E. Stine and Chi V. Dang

Nature Reviews Cancer **16**, 619–534 (2016)

On page 619 of the above article tyrosine was incorrectly referred to as an essential amino acid; this has now been corrected to tryptophan.

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.